Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6562549 | 0.75 | LMNA (0.35) | LMNACA2EPHX1MEN1KMT2A | |
| SCHEMBL6562574 | 0.72 | EPHX1 (0.39) | LMNACA2CCR5EPHX1MEN1 | |
| SCHEMBL6561474 | 0.71 | KCNH2 (0.38) | LMNACCR5EPHX1MEN1KMT2A | |
| SCHEMBL6563449 | 0.70 | MEN1 (0.37) | LMNACA2MEN1KMT2AALDH1A1 | |
| SCHEMBL7105865 | 0.69 | MEN1 (0.42) | LMNACA2MEN1KMT2AALDH1A1 | |
| SCHEMBL6562558 | 0.67 | LMNA (0.38) | LMNACA2EPHX1MEN1KMT2A | |
| SCHEMBL10920262 | 0.66 | ITGA4 (0.51) | EPHX1 | |
| SCHEMBL15910006 | 0.65 | EPHX1 (0.50) | LMNACA2EPHX1ALDH1A1MME | |
| SCHEMBL10923844 | 0.65 | ITGA4 (0.58) | MEN1KMT2ASIGMAR1 | |
| SCHEMBL5869394 | 0.64 | FOLH1 (0.51) | LMNACA2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040258620-A1 | (Ethylene)-( propylene)-triaminepentaacetic acid derivatives, process for their production, and their use for the production of pharmaceutical agents | SCHERING AG (DE) | 2004-12-23 | — | — | US | disclosed |
| EP-1397339-A1 | (ETHYLENE)-(PROPYLENE)-TRIAMINEPENTAACETIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS | Schering Aktiengesellschaft (DE) | 2004-03-17 | — | — | EP | disclosed |
| US-20030194371-A1 | (Ethylene)-(propylene) - triaminepentaacetic acid derivatives, process for their production, and their use for the production of pharmaceutical agents | SCHERING AG (DE) | 2003-10-16 | — | — | US | disclosed |
| WO-2003000647-A1 | (ETHYLENE)-(PROPYLENE)-TRIAMINEPENTAACETIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS | SCHERING AG (DE) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040258620-A1 | (Ethylene)-( propylene)-triaminepentaacetic acid derivatives, process for their production, and their use for the production of pharmaceutical agents | EEA1, PCTP, TTPA | LMNA 3545/4885CA2 3233/4885CCR5 707/4885 |
| US-20030194371-A1 | (Ethylene)-(propylene) - triaminepentaacetic acid derivatives, process for their production, and their use for the production of pharmaceutical agents | PGD, AADAT, TRHDE | LMNA 3353/4885CA2 3967/4885CCR5 1944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.